Eileen M. O'Reilly

Oct 1, 2024 | cancernetwork.com | Zev A. Wainberg |Eileen M. O'Reilly

Pancreatic cancers have the dubious distinction of having the lowest survival rates of any major cancer, with an overall 5-year relative survival of only 13%.1 The majority of pancreatic cancers are detected after they have already spread, with 29% of cases involving regional lymph nodes and 51% of patients receiving a diagnosis of metastatic cancer.

Dec 15, 2023 | ascopubs.org | Eileen M. O'Reilly |Andrew H. Ko |Jonathan W. Friedberg

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Dec 15, 2023 | brnw.ch | Eileen M. O'Reilly |Andrew H. Ko |Jonathan W. Friedberg

THE TAKEAWAYThe trial by Burris et al1 is a landmark study not only in the realm of pancreatic cancer but also in the larger field of clinical research.

Jul 17, 2023 | fal.cn | Eileen M. O'Reilly

Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us. Because we respect your right to privacy, you can choose not to allow some or all types of cookies.

Jun 23, 2023 | onclive.com | Eileen M. O'Reilly

Eileen M. O'Reilly, MD, gastrointestinal oncologist, Winthrop Rockefeller Endowed Chair of Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Memorial Sloan Kettering Cancer Center, discusses survival outcomes from the phase 3 NAPOLI 3 trial (NCT04083235) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).